Objective. To review the development, histological type and outcome of a cohort of patients with lupus nephritis who were managed and followed up by the specialist Bloomsbury Rheumatology Unit between 1977 and 1999.
In the past 50 yr there has been a substantial improvement in the survival of patients with systemic lupus erythematosus (SLE), with 5-yr survival increasing from 50% in 1955 to 94% in 1994 w1x. This improvement has been attributed to a number of different factors, including the more judicious use of corticosteroids, refinements in immunosuppressive therapy, more effective treatment of hypertension and cardiovascular disease, and greater availability of dialysis and renal transplantation. This improvement in overall survival is also reflected in the 5-yr survival data of patients with diffuse proliferative lupus nephritis (>80% during the past two decades compared to just 17% before 1970 w2x). Nevertheless, recent studies show that these patients remain at substantial risk of developing end stage renal disease (ESRD), with estimates varying from 10 to 70% after 5 yr w3-10x. Nossent's recent review of the literature indicates that this complication develops in ;20% of patients with lupus nephritis, a proportion not significantly different from three decades ago w11x. Studies have, therefore, focused on the prognostic value of various clinical, demographic and histological features so as to enable the development of rational guidelines for the use of potentially toxic immunosuppressive therapies in the management of lupus nephritis.
The histological findings in lupus nephritis are categorized into six classes according to World Health Organization (WHO) classification. Various studies of the prevalence of ESRD in lupus nephritis make it clear that those patients at highest risk of progression to ESRD have proliferative, WHO classes III and IV nephritis w10x. It has been suggested, therefore, that it is in these patients that the potential benefits of aggressive therapeutic intervention are most likely to outweigh the risks. In general, patients with mesangial (WHO class II) nephritis do not require treatment beyond therapy directed at the extra-renal manifestations. While patients with nephrotic syndrome due to pure membranous (WHO class V) nephritis are at particular risk of cardiovascular events and thromboembolism, the renal prognosis is more favourable than for proliferative nephritis. Treatment recommendations for both class II and V nephritis are largely based on empirical grounds and open studies. It is recommended that the focus of therapy for patients with advanced glomerulosclerosis (WHO class VI) be directed to the management of extra-renal disease, in addition to renal replacement and alleviation of the consequences of chronic renal insufficiency.
The role of intermittent, longer course cyclophosphamide in the treatment of lupus nephritis was established by two prospective, controlled clinical trials performed at the National Institutes of Health (NIH) w12, 13x and the Mayo clinic w14x in the 1970s, and more recently again at the NIH w15x. The NIH studies showed that a regimen of monthly intravenous pulses of cyclophosphamide was comparable to oral cylophosphamide in terms of efficacy, but was less toxic w16x. Although the optimal duration and frequency of pulse i.v. cyclophosphamide therapy have yet to be determined, the currently preferred regimen is monthly pulse intravenous cyclophosphamide for 6 months (CYC) followed by quarterly pulses for 2 yr.
Justifiably, concerns remain about the toxicity associated with long-term CYC, in particular premature ovarian failure (frequency increasing from 17% in patients aged <25 yr receiving >15 doses of pulse therapy to 100% in patients aged >31 yr) w16x, infection (most commonly herpes zoster) and possible malignancy. Further research is clearly needed to facilitate improved targeting of toxic therapy towards those patients at highest risk of poor outcome.
In view of the current interest in the use of i.v. CYC in the management of lupus nephritis and the relative paucity of long-term follow-up data, we have examined the outcome of patients with lupus nephritis managed by this unit since 1978. Particular attention has been paid to the relationship between outcome (ESRD and death) and therapy involving i.v. CYC, with patients being analysed according to WHO class.
Patients and methods

Patients
Patients included in the present analysis had four or more revised criteria of the American College of Rheumatology for the classification of SLE w17x and lupus nephritis. The onset of lupus nephritis was defined as the date at which sustained proteinuria (>2+ on urinary dipstick testing)uactive urinary-sediment or impairment of renal function (rise in serum creatinine) occurred. Between January 1977 and June 1999, 78 patients (28%) out of 280 with SLE managed by this unit developed lupus nephritis. Demographic factors that were defined at time of onset of lupus nephritis in all patients were age, ethnicity, sex, and duration of follow-up. Where tissue was available the histologic pattern of disease on renal biopsy and the activity and chronicity indices were recorded. All available renal biopsy specimens not previously examined by our histopathologist (M. Griffiths) were re-analysed by her. Patients with WHO class III and IV disease were also characterized for C3 complement (C3) level (by laser nephelometer; normal range 0.9-1.8 gul), antibodies to double-stranded DNA (dsDNA) (Shield Diagnostic ELISA kit, Dundee; normal range <50), serum creatinine (mM) and proteinuria on urinalysis (1+ to 3+) at the time of biopsy. Assessment of disease activity at the time of renal biopsy was made using the 'BILAG' (British Isles Lupus Assessment Group) index. This scoring system was originally developed in 1984 in an attempt to move away from the global disease activity score approach wtypified by the Systemic Lupus Erythematosus Disease 'Activity Index (SLEDAI)x', and is based upon the 'intention to treat' premise. The BILAG index is described in detail elsewhere w18, 19x. In essence, it includes a total of 86 items in eight organs or systems. Each system is allocated alphabetic scores (A-E) according to the presence or absence of a variety of clinical features (mostly) in each organusystem. A = disease that requires urgent disease-modifying therapy; B = disease that demands close attention and perhaps modification of minor therapy; C = stable mild disease; D = system previously affected but currently inactive; and E = system never involved. Global disease activity was calculated for each assessment, using the system A = 9, B = 3, C = 1, D = 0 and E = 0. The BILAG index has been shown to have a high degree of inter-rater variability and validity w19x.
Renal biopsy
The histological pattern of disease was established using WHO criteria w20x, and where tissue was available for further analysis it was scored for activity and chronicity indices (AI and CI) as described by the NIH w21x.
Treatment regimens
This is a retrospective, observational study and consequently therapeutic regimens were not standardized. Patients received varying combinations of prednisolone, azathioprine and i.v. CYC. A minority received additional treatments such as mycophenolate mofetil, cyclosporin A, tacrolimus and plasma exchange. Patients were stratified according to whether or not their treatment protocols included at least six, monthly pulses of CYC (patients receiving no i.v. CYC were assigned to group A, patients receiving i.v. CYC were assigned to group B). It is recognized that such stratification necessarily introduces a degree of bias and therefore caution is required in the interpretation of our results. However, as far as it is possible in an observational study, we have attempted to control for this by comparing the aforementioned baseline laboratory and clinical prognostic parameters in each group.
Outcome measures
The primary outcome measure was ESRD, defined by a need for renal replacement in the form of dialysis or transplantation. Death was analysed as a secondary outcome measure.
Statistical analysis
Statistical advice was taken from the statisticians based in the Department of Research and Development, University College Hospital, London. Two-tailed tests were used to estimate P-values throughout. Differences in outcome between the two groups treated with and without CYC (limited to patients with WHO class III and IV disease) were analysed by x 2 tests using Fisher's exact two-tailed test.
Results
In 21 years of follow-up, 78 (28%) of 280 SLE patients managed by our unit have developed lupus nephritis. A total of 54 out of 78 (69%) patients with lupus nephritis were treated with regimens that did not include i.v. CYC (group A) and 24 out of 78 (31%) patients were treated with regimens that did include i.v. CYC (group B). Breakdown by WHO class of both groups is illustrated in Fig. 1 .
Renal biopsy was either not performed, or the results lost, in three and one patients, respectively, of the 54 patients in group A, but in none of those in group B. AI and CI scores were not available for 13 out of 54 (24%) group A patients and four out of 22 (18%) group B patients.
During this period of follow-up, 10 out of 54 (18.5%) patients from group A and three out of 24 (12.5%) patients from group B have died. Causes of death are recorded in Tables 1 and 2. The total number of patients who progressed to ESRD is small, occurring in just 12 out of 54 (22.2%) patients in group A and six out of 24 (25%) patients in group B. Of those patients not treated with i.v. CYC, six out of 12 had class IV disease and none had class III disease. Of those who were treated with i.v. CYC, three out of six had class IV disease and three out of six had class III disease. A breakdown of patients who progressed to ESRD by WHO class is illustrated in Fig. 2 Subgroup There was no significant difference between sex, age at onset of renal disease, mean AI and mean CI between the two subgroups. Although there was a trend for group B III to have higher C3 and serum creatinine, and lower haemoglobin at time of renal biopsy, this did not reach statistical significance. However, group B III did have significantly higher anti-dsDNA antibodies at time of renal biopsy (P < 0.02). The mean duration of follow-up is significantly longer in group A III compared with group B III (mean " S.D. 15.2 " 9 yr compared with 4.0 " 2.7 yr; P < 0.03). Again there was no significant difference between the two subgroups in terms of sex, age at onset of renal disease, mean AI or mean CI. Mean ("S.D.) duration of follow-up was 12.6 yr ("7.5) in group A IV compared with 6.7 yr ("4.5) in group B IV (P < 0.008). There was no significant difference in baseline parameters of disease severity at time of renal biopsy wcomplement (C3) level, anti-dsDNA antibody titre, urinary dipstick protein, serum creatinine and global BILAG scorex between the two subgroups.
Three out of 16 (18.7%) patients treated with i.v. CYC in addition to corticosteroids and azathioprine developed ESRD, compared with five out of 20 (25%) of those whose treatment regimens did not include i.v. CYC (not statistically significant).
Three out of 20 patients (15%) treated without i.v. CYC died, compared with one out of 16 (6.2%) whose treatment included i.v. CYC (not statistically significant).
Discussion
Since the number of patients assessed is relatively small, our analysis has been restricted to patients with WHO class III and IV nephritis. As well as being the largest subgroups, these patients are also deemed to be at highest risk of progression to ESRD [10] and, therefore, are most likely to warrant consideration of aggressive therapy.
We observed that patients with WHO class IV disease whose therapeutic regimens included i.v. CYC faired better in terms of progression to ESRD, although there were insufficient numbers to demonstrate statistical significance.
Our data also suggested that there may be a subgroup of patients with proliferative lupus nephritis (WHO class III) for whom the use of therapeutic regimens, including at least six, monthly pulses of i.v. cyclophosphamide, is not associated with an improved renal outcome; in fact, the risk of developing ESRD was greater in these patients (P < 0.02). This finding was unexpected, although the fact that patients whose treatment included i.v. CYC had significantly higher anti-dsDNA antibodies and tended to have higher serum creatinine and lower C3 levels at time of renal biopsy, might indicate that these patients had more aggressive disease per se. The fact that there was no statistically significant difference between serum creatinine and C3 levels in the two groups at baseline may relate to the small number of patients in our series. Interestingly, however, the duration of nephritis was longer in the group of patients with class III disease who were not treated with i.v. CYC (P < 0.03). One study has identified this parameter as an adverse prognostic indicator [25] .
The literature cites a number of clinical, laboratory and demographic factors that increase the risk for ESRD in patients with lupus nephritis, many of which we have attempted to define in our population with class III nephritis. Austin associated with risk of dying. Other parameters identified by some, but not all studies as having useful value in indicating poor outcome include nephrotic-range proteinuria w24-26x, hypertension w28x, low socioeconomic status w28x, male sex w23x, age <24 yr w23, 24x and anaemia w23x.
The precise role of renal biopsy in providing additive predictive value remains a subject of debate. However, it is generally accepted that outcome predictions based on clinical information alone are significantly enhanced by information obtained from renal biopsy w22, 23x.
Goulet et al. w25x used regression tree techniques to show that combinations of serum creatinine, 24-h urine protein levels, nephrotic syndrome and duration of prior renal disease provide accurate prognostic information about lupus nephritis without recourse to biopsy. Whiting-O'Keefe et al. w29x applied a stepwise regression analysis to data collected over a 12-month period after renal biopsy in 130 patients to see if biopsy added any useful information to the clinical data. They found that the histological classification did not add significantly to the predictive power of the 'before biopsy' model. However, certain features, notably the percentage of glomeruli that had undergone sclerosis in the presence of subendothelial deposits on electron microscopy, did increase the ability to predict the effect of 12 months of treatment of lupus nephritis. The contribution of activity and chronicity indices to the predictive value of clinical and demographic data has been examined by a number of investigators. The presence of severe active histological change, resulting in an activity index >12u24 (most notably due to cellular crescents and fibrinoid necrosis) w21, 28x or a chronicity index >3u15 (i.e. extensive glomerular sclerosis, interstitial fibrosis and atrophy) w21, 24, 27x, and the combination of active and chronic renal parenchymal injury all provide additive prognostic information w22, 27, 29x. However, McLaughlan et al. w23x reported that the chronicity index was not helpful in assessing prognosis in patients with an elevated serum creatinine. The patients in our series with class III and IV nephritis were matched for both activity and chronicity indices. With the exception of anti-dsDNA antibody titres at time of renal biopsy, which were significantly higher in those patients who progressed to ESRD, the group of patients with class III nephritis were apparently matched for several parameters recognized as having good prognostic value.
In terms of long-term outcome we have recently reported that, to date, the use of cyclophosphamide in this group of patients has not been associated with excess development of any malignancy w30x.
We remain cautious about over-interpreting our data regarding the merits of i.v. CYC in the management of proliferative, particularly WHO class III nephritis as our numbers are small. Moreover, this is an observational study in which treatment regimens were not strictly standardized. Clearly, however, there remains a need to examine further the outcome of patients in this subclass in order to refine the riskubenefit ratios of their therapeutic regimens. Large prospective, randomized, controlled trials are urgently needed to help clarify these issues.
